Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cedazuridine + azacitidine
- Development stage
- Phase 3
- Lead developer
- Astex Pharmaceuticals
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Cedazuridine + azacitidine is an investigational oral fixed-dose combination of two agents for the treatment of myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML), and potentially acute myeloid leukemia (AML). Azacitidine is a pyrimidine nucleoside analogue and hypomethylating agent that incorporates into DNA and RNA, inhibiting DNA methyltransferase, leading to hypomethylation of DNA, disruption of abnormal cell growth, and induction of apoptosis in malignant cells. Cedazuridine is a cytidine deaminase inhibitor that prevents the rapid degradation of azacitidine in the gastrointestinal tract and liver, enabling effective systemic exposure when administered orally. The combination aims to provide pharmacokinetic equivalence to parenteral azacitidine while reducing treatment burden for patients[1][2][6].
- Other names
- cedazuridine/azacitidine combination agentoral azacitidine with cedazuridine
02
Targets
DNMT (DNA methyltransferase)CDA (Cytidine deaminase)
Beyond the preview
Go deeper on cedazuridine + azacitidine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cedazuridine + azacitidine.